Control of vector-borne infectious diseases by human immunity against α-Gal | Synapse

⌘+K

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Respiratory syncytial virus (RSV) vaccine recommendations for adults: a review of available global, regional, and country level recommendationsExpert Review of Vaccines · 2026
2Association of the publicly funded two-dose varicella vaccine policy with varicella incidence in Shanghai: an interrupted time series studyExpert Review of Vaccines · 2026
3Effectiveness and implementation of electronic decision support for adult vaccination in primary care: a mixed-methods quasi-experimental evaluationExpert Review of Vaccines · 2026
4Modeling the cost-effectiveness of NVX-CoV2705 and the public health impact of vaccination for the prevention of seasonal COVID-19 in the USExpert Review of Vaccines · 2026
5Progress toward HIV-1 subtype C vaccines: understanding antiviral immune mechanisms and viral adaptationExpert Review of Vaccines · 2026
6Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trialsExpert Review of Vaccines · 2026
7The socioeconomic value of adult respiratory vaccination in Australia: a benefit-cost analysisExpert Review of Vaccines · 2026
8Virus-like particle vaccines: from antigen architecture to antigen presentation and adaptive immune responsesExpert Review of Vaccines · 2026
9Cost-effectiveness analysis of pneumococcal conjugate vaccines, PCV21 vs PCV20, in adults aged ≥60 years in GermanyExpert Review of Vaccines · 2026
10Differing influenza vaccine uptake and recommendation behavior among healthcare workers in primary health centers, secondary and tertiary hospitals, and schools in a metropolis of southern ChinaExpert Review of Vaccines · 2026

More from Expert Review of Vaccines

More from Centre National de la Recherche Scientifique